98 related articles for article (PubMed ID: 1722498)
1. HIV-neutralizing antibodies: epitope identification and significance for future vaccine.
Robert-Guroff M
Int Rev Immunol; 1990; 7(1):15-30. PubMed ID: 1722498
[No Abstract] [Full Text] [Related]
2. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
[TBL] [Abstract][Full Text] [Related]
3. Recombinant multi-epitope vaccine induce predefined epitope-specific antibodies against HIV-1.
Li H; Liu ZQ; Ding J; Chen YH
Immunol Lett; 2002 Nov; 84(2):153-7. PubMed ID: 12270553
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing epitopes in the membrane-proximal region of HIV-1 gp41: genetic variability and co-variation.
Dong XN; Chen YH
Immunol Lett; 2006 Aug; 106(2):180-6. PubMed ID: 16859756
[TBL] [Abstract][Full Text] [Related]
5. Challenges of antibody-mediated protection against HIV-1.
Lewis GK
Expert Rev Vaccines; 2010 Jul; 9(7):683-7. PubMed ID: 20624038
[No Abstract] [Full Text] [Related]
6. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
[TBL] [Abstract][Full Text] [Related]
7. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.
Dong XN; Xiao Y; Chen YH
Immunol Lett; 2001 Jan; 75(2):149-52. PubMed ID: 11137140
[TBL] [Abstract][Full Text] [Related]
8. Immune systems rather than antigenic epitopes elicit and produce protective antibodies against HIV.
Van Regenmortel MHV
Vaccine; 2017 Apr; 35(16):1985-1986. PubMed ID: 28320589
[No Abstract] [Full Text] [Related]
9. Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies.
Huarte N; Lorizate M; Kunert R; Nieva JL
FEBS Lett; 2008 Nov; 582(27):3798-804. PubMed ID: 18930052
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
[TBL] [Abstract][Full Text] [Related]
11. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.
Kwong PD; Mascola JR
Immunity; 2018 May; 48(5):855-871. PubMed ID: 29768174
[TBL] [Abstract][Full Text] [Related]
13. Recombinant polypeptides from the human immunodeficiency virus reverse transcriptase define three epitopes recognized by antibodies in sera from patients with acquired immunodeficiency syndrome.
Padberg C; Nowlan S; Mermer B
AIDS Res Hum Retroviruses; 1989 Feb; 5(1):61-71. PubMed ID: 2470400
[TBL] [Abstract][Full Text] [Related]
14. HIV vaccine development--improving on natural immunity.
Johnston MI; Fauci AS
N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
[No Abstract] [Full Text] [Related]
15. HIV vaccine design and the neutralizing antibody problem.
Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
[No Abstract] [Full Text] [Related]
16. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
17. Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1.
Xiao Y; Dong X; Chen Y
Int Arch Allergy Immunol; 2000 Aug; 122(4):287-92. PubMed ID: 10971120
[TBL] [Abstract][Full Text] [Related]
18. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
van Gils MJ; Sanders RW
Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
[TBL] [Abstract][Full Text] [Related]
19. HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality.
Madhavi V; Kent SJ; Stratov I
Expert Rev Clin Immunol; 2012 Nov; 8(8):767-74. PubMed ID: 23167688
[TBL] [Abstract][Full Text] [Related]
20. Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines.
Maksyutov AZ; Bachinskii AG; Bazhan SI; Ryzhikov EA; Maksyutov ZA
J Clin Virol; 2004 Dec; 31 Suppl 1():S26-38. PubMed ID: 15567091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
